EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Impact of Enterococcus faecalis Endocarditis Treatment on Risk of Relapse

Pierre Danneels iD, Jean-François Hamel, Léa Picard, Schéhérazade Rezig, Pauline Martinet, Aurélien Lorleac'h, Jean-Philippe Talarmin, Rodolphe Buzelé, Thomas Guimard, Gwenaël Le Moal, Julia Brochard-Libois, Aurélie Beaudron und 9 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac777 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Pierre Danneels und 20 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases and Tropical Medicine, Angers University Hospital, Angers, France. Hauptthemen laut MEDLINE: Endocarditis, Endocarditis, Bacterial, Gram-Positive Bacterial Infections. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Enterococcus faecalis infective endocarditis (EFIE) is characterized by a higher frequency of relapses than other infective endocarditis. The role of the treatment on its occurrence remains poorly understood. The aim of this study was to investigate whether the antibiotic regimen could impact the risk of relapse in EFIE. Materials This was a multicenter retrospective study of patients diagnosed with definite EFIE between 2015 and 2019 in 14 French hospitals. The primary endpoint was the occurrence of relapses within the year following endocarditis diagnosis. As death was a competing risk for relapse, Fine and Gray models were used for studying risk factors and impact of treatment.

Results

Of the 279 patients included, 83 (29.7%) received the amoxicillin-gentamicin (A-G) combination, 114 (40.9%) amoxicillin-ceftriaxone (A-C), 63 (22.6%) A-G and A-C (A-G/A-C) sequentially, 9 (3.2%) amoxicillin (A), and 10 received other treatments. One-year-relapse rate was 9.3% (26 patients). Relapse occurred after a median delay of 107 days from EFIE diagnosis; 6 occurred after 6 months, and 6 were diagnosed by blood cultures in asymptomatic patients. In multivariate analysis, surgery during treatment was a protective factor against one-year relapse and death. The cumulative incidence of relapse 1 year after endocarditis was 46.2% for patients treated with amoxicillin, 13.4% with A-G, 14.7% with A-C, and 4.3% with A-G/A-C (P≥.05 in multivariate analysis).

Conclusions

Relapses after treatment of EFIE are frequent, frequently asymptomatic, and may occur more than 6 months after the initial episode.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EndocarditisEndocarditis, BacterialGram-Positive Bacterial InfectionsHumansEnterococcus faecalisRetrospective StudiesAnti-Bacterial AgentsAmoxicillinGentamicinsDrug Therapy, CombinationRecurrence

Stichwörter der Autor:innen

e. faecalisamoxicillindrug therapy combinationendocarditisrelapse

Substanzen

Anti-Bacterial AgentsAmoxicillinGentamicins

Autor:innen und Institutionen

  • Infectious Diseases and Tropical Medicine, Angers University Hospital, Angers, France.
  • Groupe d'Epidémiologie et Recherche en Infectiologie Clinique du Centre et de l'Ouest (GERICCO), France.
  • Biostatistics Department, Angers University Hospital, Angers, France.
  • Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.
  • Infectious Diseases and Tropical Medicine, La Cavale Blanche University Hospital, Brest, France.
  • Infectious Diseases and Tropical Medicine, Groupe Hospitalier Bretagne Sud, Lorient, France.

ORCID-Profile: Pierre Danneels, David Boutoille, Vincent Cattoir, Vincent Dubée

Zitieren

APA

Danneels, P., Hamel, J. F., Picard, L., Rezig, S., Martinet, P., Lorleac'h, A., Talarmin, J. P., Buzelé, R., Guimard, T., Le Moal, G., Brochard-Libois, J., Beaudron, A., Letheulle, J., Codde, C., Chenouard, R., Boutoille, D., Lemaignen, A., Bernard, L., Cattoir, V., …, & EFEMER study group (2023). Impact of Enterococcus faecalis Endocarditis Treatment on Risk of Relapse. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac777

Vancouver

Danneels P, Hamel JF, Picard L, Rezig S, Martinet P, Lorleac'h A, et al. Impact of Enterococcus faecalis Endocarditis Treatment on Risk of Relapse. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac777

BibTeX
@article{Danneels2023,
  author = {Danneels, Pierre and Hamel, Jean-François and Picard, Léa and Rezig, Schéhérazade and Martinet, Pauline and Lorleac'h, Aurélien and Talarmin, Jean-Philippe and Buzelé, Rodolphe and Guimard, Thomas and Le Moal, Gwenaël and Brochard-Libois, Julia and Beaudron, Aurélie and Letheulle, Julien and Codde, Cyrielle and Chenouard, Rachel and Boutoille, David and Lemaignen, Adrien and Bernard, Louis and Cattoir, Vincent and Dubée, Vincent and EFEMER study group, EFEMER study group},
  title = {Impact of Enterococcus faecalis Endocarditis Treatment on Risk of Relapse},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac777}
}
Kostenlos starten →